Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab Effects on Synovial Inflammation and Lymph Node Composition in SLE
2024-518966-28-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of belimumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in composition of B lineage cells in peripheral blood and Change in composition of B lineage cells in lymph nodes. Planned start Nov 2024; status: authorised.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2024-518966-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518966-28-00.